Please assess the completion status of the following clinical trial:

Trial Title: Blinded Randomized Placebo-Controlled Study Efficacy and Safety of Injectafer in ID Patients With Fibromyalgia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subject's ≥ 18 years of age, able to give informed consent to the study.~* Fibromyalgia diagnosis based on The 2011 modification of the American College of Rheumatology (ACR) 's 2010 preliminary criteria for diagnosing fibromyalgia (2011ModCr)~* A baseline score ≥ 60 on the FIQR~* Subject's current medications to treat fibromyalgia, including pain medicines, anti-depressants, sleep medications must be on a stable dose for at least 30 days.~* Subject's current narcotic medication must be on a stable dose for at least 30 days prior to randomization~* Subjects at risk for pregnancy must have a negative pregnancy test at baseline and be practicing an acceptable form of birth control: have had a hysterectomy or tubal ligation, or otherwise be incapable of pregnancy, or have practiced any of the following methods of contraception for at least one month prior to study entry: hormonal contraceptives, spermicide and barrier, intrauterine device, partner sterility.~Exclusion Criteria:~* Parenteral iron use within 4 weeks prior to screening.~* History of \> 10 blood transfusions in the past 2 years.~* Anticipated need for blood transfusion during the study.~* Known hypersensitivity reaction to any component of Injectafer® (Ferric Carboxymaltose).~* Current or acute or chronic infection other than viral upper respiratory tract infection~* Malignancy (other than basal or squamous cell skin cancer or the subject has been cancer free for ≥ 5 years).~* Active inflammatory arthritis (e.g. rheumatoid arthritis, SLE).~* Pregnant or lactating women.~* Severe peripheral vascular disease with significant skin changes.~* Seizure disorder currently being treated with medication.~* Baseline ferritin ≥ 50 ng/mL.~* Baseline TSAT ≥ 20%.~* History of hemochromatosis or hemosiderosis or other iron storage disorders.~* Known positive hepatitis with evidence of active disease.~* Hemoglobin greater than the upper limit of normal.~* Calcium or phosphorous outside the normal range.~* Known positive hepatitis B antigen (HBsAg) or hepatitis C viral antibody (HCV) with evidence of active hepatitis (i.e., AST/ALT greater than the upper limit of normal).~* Known positive HIV-1/HIV-2 antibodies (anti-HIV)~* Received an investigational drug within 30 days before randomization.~* Chronic alcohol or drug abuse within the past 6 months.~* Any other pre-existing laboratory abnormality, medical condition or disease which in view of the investigator participation in this study may put the subject at risk.~* Subject unable to comply with the study requirements.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Injectafer (Type: EXPERIMENTAL): 15 mg/kg up to 750 mg undiluted blinded dose of IV Injectafer (ferric carboxymaltose) at 100 mg/minute
- Placebo (Type: PLACEBO_COMPARATOR): 15 cc of Normal Saline IV push at 2 ml/minute

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete